Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 190Lung Neoplasms 67Ovarian Neoplasms 64Breast Neoplasms 38Fallopian Tube Neoplasms 33Small Cell Lung Carcinoma 31Parkinson Disease 4, Autosomal Dominant Lewy Body 27Carcinoma, Ovarian Epithelial 24Uterine Cervical Neoplasms 22Triple Negative Breast Neoplasms 22Squamous Cell Carcinoma of Head and Neck 19Neuroblastoma 17Carcinoma 17Adenocarcinoma of Lung 17Neoplasm Metastasis 15Endometrial Neoplasms 14Neoplasms 12Head and Neck Neoplasms 11Recurrence 8Peritoneal Neoplasms 8Carcinoma, Transitional Cell 8Esophageal Neoplasms 7Central Nervous System Neoplasms 7Brenner Tumor 7Urinary Bladder Neoplasms 6Lung Diseases 6Adenocarcinoma, Bronchiolo-Alveolar 6Thoracic Neoplasms 5Testicular Neoplasms 5Respiratory Tract Neoplasms 5

Interventions

Etoposide 3Cisplatin 2Carboplatin 2belotecan 1atezolizumab 1RRx-001 1PM 01183 1EC regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Carcinoma, Small Cell × Carboplatin × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT03699956 2024-03-26

REPLATINUM

EpicentRx, Inc.

Phase 3 Terminated
18 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡